Integer Holdings Corporation Shareholder Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Integer common stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, indicating that legal proceedings are underway.
- Potential Compensation Opportunity: Investors participating in the class action may receive compensation without any out-of-pocket costs, which reduces the financial burden on investors and encourages more affected parties to join.
- Overview of Allegations: The lawsuit alleges that Integer overstated its competitive position in the electrophysiology device market and failed to disclose declining sales, resulting in investor losses when the true situation became known, highlighting a lack of transparency in the company's disclosures.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
ITGR
$78.71+Infinity%1D
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 91.75 USD with a low forecast of 69.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 77.770
Low
69.00
Averages
91.75
High
140.00
Current: 77.770
Low
69.00
Averages
91.75
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
